NEW: Additional SARS-CoV-2 PepMixes™ & Antigen Peptides
Published on 31/05/2021
JPT appreciates your valuable feedback on our previously launched COVID-19 products. In response to your suggestions and to enable SARS CoV-2 research, we continue to develop and manufacture innovative products for scientific progress around the world.
Here is an update on what is new this week:
1. New PepMix™ Peptide Pools
In order to study the specificity of cellular immune responses against SARS CoV-2 and potential immunity caused by other human Corona Viruses, we will soon finalize Spike protein peptide pools of all relevant common cold Corona Viruses, namely HCoV-NL63, HCoV-HKU1, HCoV E229, and HCoV OC43. Furthermore, we are launching a peptide pool of the Receptor Binding Domain (RBD) of SARS-CoV-2 Spike Glycoprotein.
2. Individual Antigen Peptides for SARS-CoV-2 Spike glycoprotein, NCAP and VME1
Individual antigen peptides derived from studies on the human immune response to SARS virus, are very similar to SARS-CoV-2. SARS-CoV-2 sequences which are identical (28 peptides) or similar (13 peptides with 1, 7 with 2 and 1 with 3 mutations) to experimentally confirmed SARS epitopes are available through our shop. These peptides can be used for antigen specific T-cell stimulation in T-cell assays or T-cell expansion.
For a complete overview of all COVID-19 related products please visit: https://www.jpt.com/clinical-indications/infections/sars-cov-2/
Further SARS CoV-2 related products are under development and will be launched within the next few weeks.